Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00592371
  4. Details
NCT00592371 Clinical Trial

Head and Neck Cancer Screening and Serum Repository

Head and Neck Squamous Cell Cancer Clinical Trial

Official title:
Head and Neck Cancer Screening and Serum Repository

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00592371
Other study ID # 59102
Secondary ID
Status Completed
Phase N/A
First received December 27, 2007
Last updated September 4, 2012
Start date March 2006
Est. completion date September 2012

Study information
Verified date September 2012
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol. Survival is related to stage of HNSCC when treatment is sought. Most HNSCC patients present with advanced staged disease. This screening activity will educate patients with HNSCC rick factors and screen for pre malignant and/or early staged lesions.

Description:

Otolaryngology staff memebers and residents will perform head and neck examinations upon participants after the participant has completed their questionnaire and had the opportunity to partcipate in the research portion by having blood drawn. A suspicious head and neck examination will be considered abnormal, and further recommendations for follow-up will be made. Participants will be provided with a list of practicing head and neck surgeons within the state of Arkansas.

Recruitment information / eligibility
Status Completed
Enrollment 300
Est. completion date September 2012
Est. primary completion date September 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Exclusion Criteria:

- Under the age of 18 years of age

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States University of Arkansas for Medical Sciences Little Rock Arkansas

Sponsors (1)
Lead Sponsor Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03667482 - Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 1
Completed NCT02083692 - Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Early Phase 1
Completed NCT02282371 - Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) Phase 1
Active, not recruiting NCT03138070 - A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 N/A
Active, not recruiting NCT02159508 - Intensive Nutrition Counselling in Patients With Head and Neck Cancer N/A
Completed NCT02252042 - Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Phase 3
Terminated NCT01790516 - Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer N/A
Completed NCT00574977 - Safety Study of Modified Vaccinia Virus to Cancer Phase 1
Recruiting NCT02485548 - Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Phase 3
Terminated NCT01326923 - Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer Phase 2
Not yet recruiting NCT03975270 - Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) Phase 2
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Recruiting NCT02327468 - Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers Phase 1
Active, not recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1
Terminated NCT00260598 - LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer Phase 2
Completed NCT02163057 - Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04856631 - A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer Phase 1/Phase 2